Verve pauses lead base editing program, to focus on follow-up poised for human testing this quarter

Verve Therapeutics is pausing work on its lead gene editing treatment, which was the first time base editing was used to directly alter DNA in humans, after a serious adverse event. The biotech will turn its focus to a similar candidate with a different type of lipid…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks